RECENT FUNDING ROUNDS
| Company | Country | Profile | Funding round | Value | Date | |
|---|---|---|---|---|---|---|
|
Neurelis Inc | Neuroscience company. | Series D | USD 114,000,000 |
MOST ACTIVE INVESTORS
| Catalio Capital Management | 1 |
BEST FUNDED
Clinical-stage neuroscience company leveraging a platform technology that enabling selective delivery of therapeutic agents across the blood barrier.